Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.
about
Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patientsReview of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramificationsImpact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancersPreoperative evaluation and oncologic principles of colon cancer surgeryEGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndromeLow frequency of defective mismatch repair in a population-based series of upper urothelial carcinomaMicrosatellite instability analysis in hereditary non-polyposis colon cancer using the Bethesda consensus panel of microsatellite markers in the absence of proband normal tissue.Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesisColorectal cancer: A review of the genome-wide association studies in the kingdom of Saudi ArabiaMismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC)A review of the clinical relevance of mismatch-repair deficiency in ovarian cancerAlterations of copy number of methylation pattern in mismatch repair genes by methylation specific-multiplex ligation-dependent probe amplification in cases of colon cancerEndometrial cancer and Lynch syndrome: clinical and pathologic considerationsInvestigation on the role of nsSNPs in HNPCC genes--a bioinformatics approach.Familial gastric cancer: overview and guidelines for management.Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry.BayesMendel: an R environment for Mendelian risk predictionKnowledge about hereditary nonpolyposis colorectal cancer; mutation carriers and physicians at equal levels.Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management.Genetic implications of double primary cancers of the colorectum and endometrium.Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancerSurvey of HNPCC Management Analysis of Responses from 18 International Cancer Centres.Functional analysis of human mismatch repair gene mutations identifies weak alleles and polymorphisms capable of polygenic interactions.Genetic susceptibility to non-polyposis colorectal cancer.Age-Dependent Cancer Risk Is Not Different in between MSH2 and MLH1 Mutation Carriers.Clinical challenges in management of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer.Underdiagnosis of Lynch syndrome involves more than family history criteriaMolecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene.Lower gastrointestinal tract cancer predisposition syndromesDNA mismatch repair genes and colorectal cancer.Diagnostic yield of repeat capsule endoscopy and the effect on subsequent patient managementThe efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.The Family Health Promotion Project (FHPP): design and baseline data from a randomized trial to increase colonoscopy screening in high risk families.Application of molecular diagnostics for the detection of Lynch syndrome.Clinicopathological and genetic features of Chinese hereditary nonpolyposis colorectal cancer (HNPCC).hMLH1 promoter methylation and BRAF mutations in high-frequency microsatellite instability colorectal cancers not fulfilling the revised Bethesda guidelines.Interval colon cancer in a Lynch syndrome patient under annual colonoscopic surveillance: a case for advanced imaging techniques?10 rare tumors that warrant a genetics referral.Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research.Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.
P2860
Q21328691-606DB64B-46E0-423B-AF73-85A59EF1298AQ24610838-F8507303-B862-4171-8E6F-F7D5B20E01E1Q24611865-48E8FF34-2369-45C2-AD77-C6F709DAE150Q24653695-654097BD-5B21-461D-BDC0-A636BF49E7EFQ24655053-2E466306-858D-44D8-B32B-69C7AC7D7F3EQ24803223-B6804D56-9489-4138-9271-959C61136F60Q25257189-B83A4D14-3375-48C4-8CD3-59E46C438A7AQ25257401-477BE284-AFB6-4572-BA95-16EB2A5CAF02Q28084830-56283F9A-F48A-432E-B72F-96C0EC473FE6Q28202312-9D683BDE-B75C-4885-BF4C-E0AF64741AB9Q28283356-707C3588-A7BE-4B9D-AB39-F8AFCD600D3BQ28298882-EAE0F043-925A-4469-84C5-8D9C787D769BQ28303873-7152B55C-B7B9-4374-B36D-D5A97C4B4B5BQ30376403-04E507AD-DE82-4A53-961B-BE2320628BDDQ30443024-D3B06133-8A37-494B-9F4D-B8C1FB433217Q33208352-5A108C0B-E413-4B3E-857C-80E4E0A354B2Q33241509-3B3D69B5-B0C4-4F1C-A948-4FB7E7F84DA0Q33422607-A6A65EA4-BE36-4284-8DB9-254711C1CAB1Q33582756-EE6FBC97-4E1A-4B2A-97B2-13CBBB8622FBQ33681640-F83EBC23-B34C-4A2D-918F-AC47890C35A9Q33711113-7ACF8CC1-E789-4636-9965-F5143AE7C417Q33721542-DB564437-D6F7-4FFF-BC7D-96860A3E15D8Q33739955-D2F6935C-1F02-4590-92E1-ED5348726BCDQ33764029-8229B6E4-E5DE-4551-98B7-31D132105BA2Q33807931-04FE7F53-C627-4E9C-9EA4-CB45AC35A569Q33813997-C6FC8CC4-CDF7-4545-9297-069350C15094Q33889119-B0683335-1907-402F-B2BA-64B7A5647685Q33904639-F778C79F-E944-41EB-A2FC-0313F1209186Q33920573-F204F311-B814-4878-9408-EFD7E62A9E05Q33947053-0859D48A-3100-4A9C-9E2C-5B421227655CQ34053325-A3C521E3-207F-4BDD-9E17-62D789276427Q34053682-EB45F48B-77F9-4941-A896-4F78AA9D0B28Q34078901-601D52D7-9CA7-4F7F-BE87-CAAA6CF4B9A4Q34088809-4445F1BB-990F-4FBF-A2F9-36204907653BQ34174654-F47F36BA-AF7A-43DC-9868-F6C3F1F1411EQ34221477-8E678C7C-B151-445A-9900-1AC204669B1BQ34280607-0DDA34D2-02F5-4609-B564-8B8C99EBCB59Q34325954-3FC8A895-5685-4723-B02C-67DB9BBA6C5CQ34346468-2A624F5F-E213-4390-87ED-1C717D5BBB08Q34346668-4388889F-6D8B-4D9F-A166-1D2832191657
P2860
Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.
description
1996 nî lūn-bûn
@nan
1996 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Cancer risk in families with h ...... iagnosed by mutation analysis.
@ast
Cancer risk in families with h ...... iagnosed by mutation analysis.
@en
Cancer risk in families with h ...... iagnosed by mutation analysis.
@nl
type
label
Cancer risk in families with h ...... iagnosed by mutation analysis.
@ast
Cancer risk in families with h ...... iagnosed by mutation analysis.
@en
Cancer risk in families with h ...... iagnosed by mutation analysis.
@nl
prefLabel
Cancer risk in families with h ...... iagnosed by mutation analysis.
@ast
Cancer risk in families with h ...... iagnosed by mutation analysis.
@en
Cancer risk in families with h ...... iagnosed by mutation analysis.
@nl
P2093
P50
P3181
P1433
P1476
Cancer risk in families with h ...... diagnosed by mutation analysis
@en
P2093
E H Meijers-Heijboer
F M Nagengast
G Griffioen
J H Kleibeuker
J T Wijnen
M L Bisgaard
P304
P3181
P356
10.1053/GAST.1996.V110.PM8612988
P407
P577
1996-04-01T00:00:00Z